Arkolith/Insider Trading/ELVN/Form 4

Collins Helen Louise

CHIEF MEDICAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Mar 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2026Sell(S)10K$30.19$306K25K
Mar 10, 2026Option exercise(M)10K$2.48$25K35K
Mar 9, 2026Sell(S)30K$30.02$897K25K
Mar 9, 2026Option exercise(M)30K$2.48$74K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 10, 2026Option exercise(M)10K—$0181K
Mar 9, 2026Option exercise(M)30K—$0191K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001701247-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML